Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Hidehiko, Fukahori"'
Autor:
Yuka Kawato, Hidehiko Fukahori, Koji Nakamura, Kaori Kubo, Masaki Hiramitsu, Fumitaka Kinugasa, Tatsuaki Morokata
Publikováno v:
European journal of pharmacology. 938
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multi-organ systems with a widely heterogeneous clinical presentation. Renal involvement, observed mainly in lupus nephritis (LN), is the most common organ lesion associated with S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b569cb15b107756fcef10c395ee16f91
https://pubmed.ncbi.nlm.nih.gov/36463947
https://pubmed.ncbi.nlm.nih.gov/36463947
Autor:
Yuuki Naganuma, Masashi Maeda, Koji Nakamura, Hidehiko Fukahori, Hiroyuki Satake, Ryuji Murakami, Kaori Hanaoka, Yasuyuki Higashi, Hironari Koyama, Tatsuaki Morokata
Publikováno v:
Transplant immunology. 75
Non-human primate (NHP) renal transplantation models are widely used vivo models for researching new immunosuppressive therapies including allograft tolerance strategies. To enroll animals into a tolerance study, an immunosuppressive regimen that eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3c4746ad6ca3e23ff76cde51bba2449
https://pubmed.ncbi.nlm.nih.gov/36057381
https://pubmed.ncbi.nlm.nih.gov/36057381
Autor:
Fumitaka Kinugasa, Itsuo Nagatomi, Hirofumi Ishikawa, Tomonori Nakanishi, Masashi Maeda, Jun Hirose, Hidehiko Fukahori, Shinsuke Ooshima, Takahisa Noto, Yasuyuki Higashi, Nobuo Seki, Seitaro Mutoh
Publikováno v:
Journal of Pharmacological Sciences, Vol 108, Iss 4, Pp 529-534 (2008)
Many studies have examined the efficacy of tacrolimus in rats and dogs, but few have reported its evaluation in cynomolgus monkeys. The aim of this study was to clarify the efficacy of tacrolimus in a cynomolgus monkey renal transplant model based on
Externí odkaz:
https://doaj.org/article/22f22dcf135c4215a470c52cf63118d6
Autor:
Hidehiko Fukahori, Kaoru Yamagami, Satoshi Kubo, Yukihito Sugano, Fumie Takahashi, Ayako Moritomo, Koji Kato, Susumu Yamaki, Koji Nakamura, Koji Yokoo, Toshihiro Hamajima, Suzuki Daisuke
Publikováno v:
Bioorganic & Medicinal Chemistry. 27:1056-1064
Chemical optimization of the 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (THPP) scaffold was conducted with a focus on cellular potency while maintaining high selectivity against PI3K isoforms. Compound 11f was identified as a potent, highly selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f4885a30545480350b0f2b6589425c
https://doi.org/10.1016/j.bmc.2019.02.001
https://doi.org/10.1016/j.bmc.2019.02.001
Autor:
Tatsuaki Morokata, Shoji Takakura, Hidehiko Fukahori, Koji Nakamura, Shinsuke Oshima, Jun Hirose, Yasuyuki Higashi, Takahisa Noto, Susumu Tsujimoto, Masashi Maeda, Kaori Hanaoka
Publikováno v:
Transplant Immunology. 52:32-39
We examined the benefit of a loading dose of tacrolimus on the production of donor-specific antibodies (DSA), occurrence of acute rejection (AR) episodes, graft survival, and histological evidence of antibody-mediated rejection (ABMR) after kidney tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa37e6e8fa6841bb7a7579b11077d276
https://doi.org/10.1016/j.trim.2018.10.004
https://doi.org/10.1016/j.trim.2018.10.004
Autor:
Yuka, Kawato, Hidehiko, Fukahori, Koji, Nakamura, Atsuo, Kanno, Kaori, Kubo, Masaki, Hiramitsu, Toshihiro, Matsuda, Yuichi, Hanada, Takako, Furukawa, Yutaka, Nakajima, Fumitaka, Kinugasa, Tatsuaki, Morokata
Publikováno v:
European Journal of Pharmacology. 919:174826
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the dysregulation of various cell types and immunological pathways. Autoantibodies play an important role in its pathogenesis. The presence of autoantibodies suggests that s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd30e412726b981716ef03d759c8492c
https://doi.org/10.1016/j.ejphar.2022.174826
https://doi.org/10.1016/j.ejphar.2022.174826
Autor:
Misato Ito, Kaoru Yamagami, Takanori Marui, Koji Kato, Tatsuaki Morokata, Tomoko Kawashima, Masahiko Akamatsu, Yoko Kaneko, Fumie Takahashi, Hidehiko Fukahori
Publikováno v:
International immunopharmacology. 87
Phosphoinositide 3-kinases generate lipid-based second messengers that control an array of intracellular signaling pathways. In particular, phosphoinositide 3-kinases delta (PI3Kδ) is expressed primarily in hematopoietic cells and plays an important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb056144fe3be97720f2fc059c8967f
https://pubmed.ncbi.nlm.nih.gov/32736191
https://pubmed.ncbi.nlm.nih.gov/32736191
Autor:
Koichiro Mukoyoshi, Kaoru Yamagami, Kousei Yoshihara, Koji Yokoo, Susumu Yamaki, Fumie Takahashi, Toshihiro Hamajima, Yukihito Sugano, Koji Kato, Hidehiko Fukahori, Ayako Moritomo
Publikováno v:
Bioorganic & Medicinal Chemistry. 26:2410-2419
Phosphatidylinositol-3-kinase (PI3K)δ inhibition is one of the most attractive approaches to the treatment of autoimmune diseases and leukocyte malignancies. Through the exploration of pyrazolopyridine derivatives as potential PI3Kδ inhibitors, com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ec92c15654c1c5276396c3ef1540be
https://doi.org/10.1016/j.bmc.2018.03.042
https://doi.org/10.1016/j.bmc.2018.03.042
Autor:
Takahisa Noto, Yuka Kawato, Kaori Kubo, Tatsuaki Morokata, Yoko Kaneko, Hidehiko Fukahori, Tomonori Nakanishi, Masamichi Inami, Misato Ito, Masashi Maeda, Jun Hirose, Kaori Hanaoka, Koji Nakamura
Publikováno v:
Transplant Immunology. 46:14-20
Background Janus kinase (JAK) inhibitors are thought to be promising candidates to aid renal transplantation. However, the effectiveness of JAK inhibitors against features of chronic rejection, including interstitial fibrosis/tubular atrophy (IF/TA)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80210b8fdc9ef080d878afb7471f971c
https://doi.org/10.1016/j.trim.2017.10.001
https://doi.org/10.1016/j.trim.2017.10.001
Autor:
Yasutomo Fujii, Shingo Nakayamada, Hidehiko Fukahori, Yukihiro Kitanaga, Satoshi Kubo, Yutaka Nakahara, Yoshiya Tanaka, Emiko Imamura
Publikováno v:
Rheumatology (Oxford, England)
Objectives Peficitinib, a novel Janus kinase (JAK) inhibitor, demonstrated promising results in treating RA in phase 3 clinical trials. This in vitro study was undertaken to characterize the pharmacological properties of peficitinib and investigate t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6ad63007c70e3d7f9c6435fb7177cf
https://pubmed.ncbi.nlm.nih.gov/31764973
https://pubmed.ncbi.nlm.nih.gov/31764973